Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.

Article Details

Citation

Copy to clipboard

Yin L, Lucas S, Maurer F, Kazmaier U, Hu Q, Hartmann RW

Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.

J Med Chem. 2012 Jul 26;55(14):6629-33. doi: 10.1021/jm3003872. Epub 2012 Jul 12.

PubMed ID

22788843 [ View in PubMed

]

Abstract

CYP11B1 inhibition is a promising therapy for Cushing's syndrome. Starting from etomidate, references I and II, the title compounds were designed and synthesized. Cyclopropyl analogue 4 was identified as a CYP11B1 inhibitor more potent (IC(50) = 2.2 nM) than leads and more selective (SF = 11) than I and metyrapone. Since it also showed potent inhibition of rat CYP11B1 and good selectivity over human CYP17 and CYP19, it is a promising candidate for further development.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Abiraterone	Steroid 17-alpha-hydroxylase/17,20 lyase	IC 50 (nM)	72	N/A	N/A	Details